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Novelty and Impact 
Theoretically, time from breast cancer diagnosis to therapeutic surgery should affect 
survival but it is uncertain whether this holds true in a modern healthcare setting. The 
present study shows that even fairly short intervals from breast cancer diagnosis to 
surgery are associated with survival. Our findings suggest that the time interval 
between diagnosis and therapeutic surgery should be kept as short as possible 




Theoretically, time from breast cancer diagnosis to therapeutic surgery should affect 
survival. However, it is unclear whether this holds true in a modern healthcare setting 
in which breast cancer surgery is carried out within weeks to months of diagnosis. 
 
This is a population- and register-based study of all women diagnosed with invasive 
breast cancer in the Stockholm-Gotland healthcare region in Sweden, 2001 - 2008, 
and who were initially operated. Follow-up of vital status ended 2014. 7017 women 
were included in analysis. Our main outcome was overall survival. Main analyses 
were carried out using Cox proportional hazards models. We adjusted for likely 
confounders and stratified on mode of detection, tumor size and lymph node 
metastasis. 
 
We found that a longer interval between date of morphological diagnosis and 
therapeutic surgery was associated with a poorer prognosis. Assuming a linear 
association, the hazard rate of death from all causes increased by 1.011 (95% CI 
1.006 to 1.017) per day. Comparing, e.g., surgery 6 weeks after diagnosis to surgery 
3 weeks after diagnosis, thereby confers a 1.26-fold increased hazard rate. The 
increase in hazard rate associated with surgical delay was strongest in women with 
largest tumors. Whilst there was a clear association between delays and survival in 
women without lymph node metastasis, the association may be attenuated in 
subgroups with increasing number of lymph node metastases. We found no evidence 












In women worldwide, breast cancer is the most common cancer and leading cause of 
cancer death. Although breast cancer incidence has risen during the past decades, 
mortality has decreased. Surgery is the primary treatment for most breast cancers. 
Depending on patient characteristics, surgical radicality, stage, and tumor 
characteristics, adjuvant treatment with systemic therapy and radiotherapy may be 
given postoperatively. Delaying time to surgery will postpone all following oncologic 
treatment.  
 
The magnitudes of the benefits and harms of mammography screening have been 
much debated due to controversies regarding the validity and relevance of the 
performed randomized controlled trials 1-5. However, most reviews have concluded 
that mammography screening does reduce breast cancer-specific mortality 6-9.  If 
early detection decreases mortality, then shorter intervals to therapeutic surgery 
should also improve prognosis. However, whereas screening intervals are 
recommended to be 18 to 24 months long in Sweden, most patients are operated 
within weeks to months. Lastly, many advances in breast cancer treatment have 
been made, radically improving breast cancer prognosis 10-13. Thus, although the time 
interval between date of breast cancer diagnosis and surgery theoretically should 
have an impact on prognosis, the interval may be too short and/or the effect too small 
to influence survival in the modern healthcare setting.  
 
Studies that have investigated the association between time from breast cancer 
diagnosis to first treatment and survival are inconclusive 14-21, possibly owing to 
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differences in calendar periods, study populations, cut-offs and starting (e.g. 
physician referral vs morphological diagnosis) and end (e.g. surgery vs neoadjuvant 
therapy) points for calculating delays. The two, to date, largest studies, both 
published by Bleicher et al., 19 have found an association between increased time to 
surgery and worse survival. However, they included delays up to 180 days which 
may introduce bias since delays of this length are not random but could rather be due 
to e.g. severe comorbidity. The studies were further based on the SEER-Medicare 
and National Cancer Database (NCDB) populations, respectively. The former 
database only includes patients covered by Medicare and the latter is a hospital-
based registry including 73% of breast cancer patients and with lower completeness 
for certain ethnicities and elderly patients 22. The Swedish healthcare system, on the 
other hand, includes all Swedish residents, and the Regional Breast Cancer Register 
of Stockholm-Gotland, on which this study is based, has a completeness of 98% 23.  
 
It is known that there is an increased risk of tumor cell dissemination in higher stage 
disease 24. Hence, there may be an association between time to surgery and 
prognosis in higher stage breast cancer due to the postponement of systemic 
therapy. On the other hand, other factors, such as tumor aggressiveness and 
chemotherapy sensitivity, may be more important than timing in women who already 
have micrometastatic spread. Previous studies that have investigated possible 
differences in the relationship between time to surgery and survival based on stage 
are inconsistent 15, 19. Stage is a variable composed of both tumor size and lymph 
node status (as well as assessment of distant metastasis). Whereas both of these 
tumor characteristics can be proxies for aggressiveness, they reflect different aspects 




Using a population-based breast cancer cohort capturing in principle all of the breast 
cancer cases within a Swedish healthcare region, we sought to investigate if also 
shorter intervals from breast cancer diagnosis to therapeutic surgery are associated 
with survival. We further wished to study this association stratifying on mode of 
detection, and separately stratifying on tumor size and lymph node metastasis, 
which, to our knowledge, has not been previously studied.  
 
Materials and Methods 
Women diagnosed with an invasive breast cancer between January 1, 2001 and 
December 31, 2008 in the healthcare region of Stockholm-Gotland in Sweden, were 
identified through the Regional Breast Cancer Register. The register includes 
information on diagnosis, surgery, postoperative treatment, tumor characteristics, and 
follow-up and has a completeness of 98% 23. Using the unique personal identity 
number assigned to all Swedish residents, additional information was retrieved from 
the nationwide Swedish Cancer Register, the National Patient Register, the 
Mammography Screening Database, and the Cause of Death Register. The Cause of 
Death Register covers all residents in Sweden with essentially no missing deaths and 
has been shown to correctly classify 98% of breast cancer deaths 25. The follow-up of 
vital status is therefore virtually complete. The Mammography Screening Database 
kept at the Stockholm-Gotland Regional Cancer Center holds information on 
attendance, outcomes and dates of all visits within the population-based 
mammography screening program in Stockholm-Gotland. We retrieved information 
on somatic and psychiatric comorbidity using the National Patient Register which has 
nationwide coverage for inpatient hospitalizations in Sweden since 1987. Specialized 
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outpatient clinics are also obligated to report to the National Patient Register since 
2001. Diagnoses are coded according to the International Code of Diseases (ICD). 
Inpatient and outpatient coverage is approximately 100% 26 and 87% 27, respectively, 
and validity is high 26, 28, 29 We thus had information on all reported primary and 
secondary diagnoses for all inpatient hospitalizations and specialized outpatient visits 
since 1987 and 2001, respectively, and to end of follow-up for our study subjects.  
 
We identified 9191 women with a diagnosis of invasive breast cancer in Stockholm-
Gotland during the study inclusion period of which 8229 women were initially 
operated. Hence, only women with stage 1 to 3 disease and women who did not 
receive neoadjuvant therapy were eligible. Exclusions are depicted in Figure 1. 
Women who had the same recorded date for both breast cancer diagnosis and 
surgery were excluded since these women either 1) underwent diagnostic operations; 
2) were pre-operatively diagnosed with in situ breast cancer but where postoperative, 
pathology reports showed an invasive component; or 3) had an incorrectly recorded 
date of diagnosis. Patients in the first group are more likely to have non-symptomatic, 
small lesions with no axillary involvement 30, 31, since these are most difficult to detect 
preoperatively. The same rationale applies to the second group – i.e. that these 
patients are more likely to have smaller invasive components and no axillary 
involvement since they were not detected preoperatively. These two groups will 
therefore to a greater extent be composed of cancers of a lower stage than the 
general breast cancer population (which we also found in our study population (data 
not shown)), and, thus, also have a better survival which would skew the association 
between time to surgery and prognosis. We further excluded all women who had >63 
days from date of diagnosis to date of surgery. Delays of this magnitude are not 
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spurious but rather due to e.g. more severe comorbidity or possibly erroneous coding 
of neoadjuvant therapy, both of which would affect the analysis of prognosis. The cut-
off of 63 days was selected since this is the minimum time in which four cycles of 
neoadjuvant chemotherapy could be administered and this was a commonly 
administered amount of cycles in the neoadjuvant setting in the Stockholm-Gotland 
healthcare region during the inclusion period. Our final study population comprised 
7017 women.  
 
For all outcomes, follow-up started at date of morphological diagnosis (code 5 
diagnosis based on a fine needle aspiration or a core needle biopsy). Since 
information on vital status was available until November, 2014, but  information on 
cause of death only was available throughout 2013, follow-up ended on date of 
death, emigration, or, if these events did not occur, in November, 2014, for overall 
survival and December, 2013, for breast cancer-specific survival. Follow-up of distant 
recurrence ended five years after date of diagnosis, date of distant metastasis, death, 
or emigration, whichever came first. We restricted the follow-up of distant metastasis 
to five years in order to try to achieve as high completeness as possible.  
 
Statistical analysis 
Time to surgery was primarily considered as a continuous variable since the fit of 
regression models for survival times were superior to when it was treated as a 
categorical variable. However, for the purpose of descriptive statistics and in order to 
construct Kaplan Meier curves, time to surgery was à priori categorized accordingly: 




Our main outcome of interest, decided on à priori, was overall survival since it 
contained more events and included one more year of follow-up than breast cancer-
specific survival which increases power to detect subtle differences. However, we 
also studied breast cancer-specific survival and risk of distant metastasis in order to 
confirm results. Survival analysis was performed using Kaplan Meier survival curves 
and the Cox proportional hazards model. The proportional hazards assumptions were 
examined using Schoenfeld residuals. All the assumptions of the Cox proportional 
hazards model were satisfied. We also used restricted cubic splines to investigate a 
possible non-linear relationship between time to surgery and overall survival. In order 
to compare the fits of these models which included different degrees of freedom, we 
used the Akaike Information Criterion (AIC) 32. 
 
We studied the association of time to surgery and prognosis in the population as a 
whole. Since mode of detection, tumor size and lymph node status could modify 
associations, we thereafter stratified on mode of detection (screen- vs non-screen-
detected tumors), tumor size (≤20 mm, >20 to 40mm, or >40 mm) and number of 
lymph node metastasis (0, 1 to 3, or ≥4). Categories were decided upon à priori. 
 
Age, immigration status, comorbidity according to the Charlson Comorbidity Index 
(CCI) score 33, diagnosis of a psychiatric disorder including substance abuse before 
date of breast cancer surgery, mode of detection, synchronous contralateral breast 
cancer (within three months of the primary tumor), tumor size and lymph node status 
according to pathology reports, immediate breast reconstruction, operating hospital, 
calendar period were included as potential confounders in multivariate analyses. We 
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also adjusted for planned adjuvant therapy - chemotherapy and/or trastuzumab (only 
148 women received trastuzumab and all but four of these individuals received 
chemotherapy), radiotherapy, and endocrine therapy - in order to investigate whether 
time to surgery was independently associated with survival. All of the aforementioned 
covariates were included in what was considered our main model. For approximately 
60% of our study population we could extract information on education level, BMI and 
smoking status based on questionnaire data obtained in 2009 since these individuals 
were also included in the LIBRO-1 study 34. We thus carried out sensitivity analyses 
further adjusting for these factors. For all other covariates there was a very low 
degree of missingness (0 to <3%) except for immediate breast reconstruction which 
had a missingness of 22%. A missing category was created for all variables that had 
missing values and included in analyses. In the regression analyses, all covariates 
were treated/categorized as in Table 1. 
 
Analyses were carried out using the statistical software, STATA 13.1.     
 
Results 
Descriptive statistics are summarized in Table 1 and includes all the covariates 
adjusted for. The median time to surgery was 27 days. The median follow-up time 
was 8.9 years (range 23 days to 13.9 years). There was no statistically significant 
difference in follow-up time based on time to surgery (p=0.235).  
 
Unadjusted Kaplan Meier curves for overall survival showed a poorer survival with 
increasing time to surgery (p<0.0001) (Figure 2) which was also replicated in 
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multivariate analyses using the Cox proportional hazards model (Table 2). We found 
a statistically significant association between time to surgery and each of the three 
outcomes. Each day’s delay conferred an increased hazard rate of death from all 
causes by 1.011 (95% CI 1.006 to 1.016) after full adjustment. Comparing surgery 
after 6 weeks to surgery after 3 weeks (a difference of 21 days), thus confers a 1.26-
fold (1.011^21) increased hazard rate of death. Hazard ratios (HR) were somewhat 
lower for breast cancer-specific death (1.007, 95% CI 1.000 to 1.014) and risk of 
distant metastasis within five years (1.008, 95% CI 1.001 to 1.016). We further 
adjusted for education level, BMI, and smoking status and found that point estimates 
remained unchanged for breast cancer-specific survival and risk of distant metastasis 
and virtually unchanged for overall survival (HR 1.010, 95% CI 1.006 to 1.015). Since 
associations with delays were stronger for overall survival than for breast cancer-
specific survival and distant metastasis, we hypothesized that this could be due to 
residual confounding by comorbidity since comorbidity affects both timing and type of 
surgery, timing and type of adjuvant therapy, and both breast cancer-specific deaths 
and deaths due to other causes. We therefore carried out post hoc analyses of the 
association between time to surgery and overall survival restricted to women with no 
somatic nor psychiatric comorbidity (n=5762, 849 deaths, 52193 years at risk). 
Results were somewhat attenuated and similar to point estimates for breast cancer-
specific survival and risk of distant metastasis; HR for overall survival was 1.008 
(95% CI 1.002 to 1.013, p=0.010) based on our main model and 1.007 (95% CI 1.002 
to 1.013, p=0.012) after further adjustment for education level, BMI and smoking 




We proceeded by allowing for a smooth nonlinear covariate effect using splines. 
Although we did not find convincing evidence to reject the linear model (the linear 
model had lowest AIC value, a value of 20163.4, compared to values of 20165.0 and 
20166.5 for the 2 and 3 degrees of freedom models, respectively,) the nonlinear 
models suggested that an association between time to surgery and survival may be 
strongest after around 20 days (Figure 3). The HRs comparing surgery after 6 weeks 
to surgery after 3 weeks were similar for all three models. Post-hoc, stratified analysis 
lent further support to the observation that a day’s “delay” may carry different weight 
according to its time from diagnosis; in women operated within 20 days, there was no 
statistically significant association with overall survival (HR 1.004 for each day’s 
delay; 95% CI 0.975-1.033, after full adjustment), whereas the hazard rate increased 
by 1.012 (95% CI 1.006-1.019, after full adjustment) for each day’s delay in the group 
operated 21-63 days after diagnosis.  
 
We lastly performed analyses stratifying on tumor size and lymph node metastases, 
the results of which are presented in Table 3. On the multiplicative scale (Cox 
proportional hazards model) the increase in hazard rate (from an increase in surgical 
delay), independent of outcome, was largest in the group of women with largest 
tumors (and, of course, large tumors are associated with high hazard rates). The 
interaction between time to surgery and tumor size was statistically significant for all 
three outcomes (p=0.0019 for the main model for overall survival). Based on our 
main model, the hazard rate for death from all causes increased by a factor of 1.030 
(95% CI 1.014 to 1.046) for women with tumors >40 mm, and by a factor of 1.007 
(95% CI 1.000 to 1.014) for women with tumors ≤20 mm per day’s delay. Survival 
analyses stratified on lymph node metastases revealed that, on the multiplicative 
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scale, the association between a surgical delay and an increased hazard rate of 
death was attenuated with an increasing amount of lymph node metastases 
(p=0.0001 for an interaction between time to surgery and lymph node status). Based 
on our main model, the hazard rate for death from all causes increased by a factor of 
1.012 (95% CI 1.005 to 1.019) for women with no lymph node metastases, and by a 
factor of 1.003 (95% CI 0.993 to 1.012) for women with >=4 lymph node metastases 
per day’s delay. Similar point estimates of association within each of the strata were 
seen for breast cancer-specific survival and risk of distant metastasis within five 
years, as were seen of overall survival, although they were not statistically significant. 
 
The association between time to surgery and overall survival was only statistically 
significant in non-screen-detected cancers (HR 1.010, 95% CI 1.004 to 1.015, and 
1.003, 95% CI 0.992 to 1.014, for non-screen-detected cancers and screen-detected 
cancers, respectively). However, there was no statistically, significant interaction 
between time to surgery and mode of detection (p=0.6576 for overall survival).   
 
Discussion 
Despite relatively short intervals, we found that time to therapeutic surgery from 
breast cancer diagnosis was associated with prognosis (overall survival, breast 
cancer-specific survival, and risk of distant metastasis within five years). Assuming a 
linear relationship, we found that the hazard rate of death from all causes increased 
by 1.011 per day, which, comparing e.g. surgery at 6 weeks after diagnosis to 
surgery at 3 weeks after diagnosis, would confer a 1.26-fold increased hazard rate of 
death. The association between time to surgery and survival was especially 
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pronounced in women with larger tumors. Whereas this association also was present 
in women with no lymph node metastases, the association was attenuated in 
subgroups with increasing number of lymph node metastases.  
 
A certain interval from date of diagnosis to surgery is needed to complete diagnostic 
work-up, optimize patients pre-operatively, and may also be crucial for patients to 
adjust to their cancer diagnosis and awaiting surgery. Results from non-linear models 
suggested that a day’s “delay” carried different weight according to its time from 
diagnosis; the association with overall survival seemed to be strongest after 20 days 
and weaker, if at all present, in the interval before that. Future studies with more 
power are needed to further examine this. 
 
Our finding of an association between surgical delay and an inferior survival in breast 
cancer patients is consistent with the three, previously published, population-based 
studies that have used morphological diagnosis as starting point and were confined 
to women who had surgery as initial treatment 18, 19. It is further in line with most 
studies on early detection and breast cancer mortality 6-9. Our results from analyses 
stratified on tumor size and lymph node metastasis are related to the findings of the 
NCDB cohort in the study conducted by Bleicher et al. 19 who found an association 
between time to surgery and an increased risk of death in women who had stage I 
and II disease, but not in women with stage III disease. This was not clearly seen in 
the SEER study by Bleicher et al. 19. Conversely, McLaughlin et al. only found an 
association between time to first treatment (surgery, radiotherapy or systemic 
treatment) and survival in late stage disease 15. However, the NCDB study is the only 
study with a study population comparable to ours since the SEER cohort only 
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included individuals over 65 years of age and the study by McLaughlin et al. was 
based on a cohort of low income women and included patients independent of type 
of first treatment which could explain the discrepant results. The differences in 
associations we found in subgroup analyses would be in agreement with the 
spectrum theory in which breast cancer is viewed as a heterogeneous disease; from 
tumors that remain localized throughout their entire life spans to those that already 
are disseminated at onset 35. The theory states that many breast cancers fall in 
between these two extremities, being localized at first, but, if left untreated, at some 
time point acquiring the potential to spread 35.  
 
Lymph node status is the single most significant prognostic factor of distant 
recurrence and death in women with breast cancer 36. Women with lymph node 
metastases thus reflect the women at largest risk of tumor cell dissemination which 
implies that tumor cells have spread beyond the breast and locoregional lymph 
nodes. Local treatment with e.g. surgery will therefore not have a curative potential, 
which could explain the null association between time to surgery and prognosis in 
this group. However, delaying surgery also automatically delays all following systemic 
treatment, yet initiation of adjuvant chemotherapy could have been prioritized in 
women with more advanced disease. Alternatively, other factors such as tumor 
biology and treatment efficacy may outweigh the aspect of timing of adjuvant, 
systemic therapy, for these individuals, at least within the relatively short intervals 
investigated in this study.  
 
The topic of this study is highly clinically relevant. Since it would be unethical to 
perform a randomized controlled trial with the same objective, one must rely on 
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observational studies. As with all such studies, our study has certain caveats. We 
cannot discern whether the poorer prognosis seen with increased time to surgery is 
due to delayed surgery, delayed adjuvant treatment or a combination of the two. 
There may be patient factors, other than the ones adjusted for, associated with both 
postponement of surgery and adjuvant treatment or treatment adherence. Yet, we 
believe that we adjusted for all relevant, systematic confounders, including patient 
factors such as somatic and psychiatric comorbidity. We further only allowed a fairly 
short interval to surgery, thereby excluding extremes. For a subcohort of women 34 
we had additional information on education level, BMI and smoking. Point estimates 
remained unchanged for breast cancer-specific survival and distant metastasis within 
five years and virtually unchanged for overall survival after additional adjustment. 
Thus, by adjusting for the other factors included in our main model, we believe that 
we take into account effects of socioeconomic factors on the relationship between 
time to surgery and prognosis. This may be expected in a country like Sweden where 
healthcare, including both mammography screening and breast cancer treatment, is 
publically financed, and all Swedish residents are automatically covered by the 
National Healthcare System 37. Because this study excluded women who received 
neoadjuvant therapy and women who had a diagnostic resection performed, we did 
not take tumor subtype into account since no other information on tumor 
characteristics other than tumor size and lymph node metastasis would have been 
available prior to surgery. Hence, tumor subtype could not have influenced time to 
surgery other than indirectly via age, stage and mode of detection, which were all 
adjusted for. A null association between time to surgery and subtype was also found 
in the subpopulation that had information on tumor subtype according to the St 




In observational studies, there is always a risk of residual confounding. We 
hypothesized that the differences in effect sizes between time to surgery and overall 
survival compared to the more breast cancer specific outcomes breast cancer-
specific survival and risk of distant metastasis could be due to residual confounding 
by comorbidity since comorbidity can affect timing and type of surgery as well as 
adjuvant therapy and both breast cancer specific deaths and deaths by other causes. 
After exclusion of women with both somatic and psychiatric comorbidities, we found 
that point estimates for overall survival were somewhat attenuated and similar to 
point estimates for breast cancer-specific survival and risk of distant metastasis. 
Thus, the discrepancy in effect sizes may largely be due to residual confounding by 
comorbidity.  
 
Strengths of this study include its prospective, cohort design. Furthermore, it is based 
on high quality registers with a nearly 100% coverage of breast cancer cases. Hence, 
it includes almost all women initially operated for breast cancer within the healthcare 
region of Stockholm-Gotland, independent of e.g. insurance status or survival. 
Additional strengths include the high quality of previously validated variables 
including mode of detection, low degree of missingness, virtually complete follow-up 
of vital status, and long follow-up time.   
 
Conclusion  
We have shown that even a few weeks delay from breast cancer diagnosis to 
therapeutic surgery is associated with an impaired prognosis. There may, however, 
be certain subgroups, such as women with lymph node metastases, for whom time to 
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surgery might be of less importance. For women with large tumors it may be 
particularly crucial to keep this interval at a minimum. In conclusion, the time interval 
between diagnosis and therapeutic surgery should be kept as short as possible 
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Table 1. Patient, tumor, treatment and follow-up characteristics by time to 
surgery 




1 day  











Characteristic Mean (SD) 
/n (%) 








Age  58.2 (10.8) 56.0 (10.6) 57.8 (10.7) 59.2 (10.8) 59.0 (11.5) 
BMI      
<25 2138 (30%) 257 (35%) 1013 (31%) 643 (30%) 225 (27%) 
25-30 1322 (19%) 114 (15%) 645 (20%) 431 (20%) 132 (16%) 
>=30 496 (7%) 53 (7%) 213 (6%) 167 (8%) 63 (8%) 
Unknown 3061 (44%) 321 (43%) 1412 (43%) 925 (43%) 403 (49%) 
Smoking status      
Non-smoker 1570 (22%) 172 (23%) 738 (22%) 499 (23%) 161 (20%) 
Current smoker 1319 (19%) 138 (19%) 653 (19%) 396 (18%) 132 (16%) 
Former smoker 286 (4%) 33 (4%) 135 (4%) 84 (4%) 34 (4%) 
Unknown 3842 (55%) 402 (54%) 1757 (54%) 1187 (55%) 496 (60%) 
Education level      
Low 2262 (32%) 236 (32%) 1036 (32%) 725 (33%) 265 (32%) 
High 1716 (24%) 196 (26%) 839 (26%) 520 (24%) 161 (20%) 
Unknown 3039 (43%) 313 (42%) 1408 (43%) 921 (43%) 397 (48%) 
CCIb      
0 6173 (88%) 677 (91%) 2918 (89%) 1886 (87%) 692 (84%) 
1 460 (7%) 37 (5%) 203 (6%) 159 (7%) 61 (7%) 
≥2 343 (5%) 28 (4%) 145 (4%) 108 (5%) 62 (8%) 
Unknown 41 (1%) 3 (0%) 17 (1%) 13 (1%) 8 (1%) 
Psychiatric disorderc      
No 6484 (92%) 702 (94%) 3040 (93%) 1992 (92%) 750 (91%) 
Yes 533 (8%) 43 (6%) 243 (7%) 174 (8%) 73 (9%) 
Born in Sweden      
No 1205 (17%) 112 (15%) 525 (16%) 419 (19%) 149 (18%) 
Yes 5812 (83%) 633 (85%) 2758 (84%) 1747 (81%) 674 (82%) 
Mode of detection      
Screen-detected breast 
cancers 
2392 (34%) 273 (37%) 1230 (37%) 692 (32%) 197 (24%) 
Non-screen-detected 
breast cancers  
4535 (65%) 461 (62%) 2014 (61%) 1445 (67%) 615 (75%) 
Unknown 90 (1%) 11 (1%) 39 (1%) 29 (1%) 11 (1%) 
Calendar period      
2001-2003 2601 (37%) 306 (41%) 1235 (38%) 752 (35%) 308 (37%) 
2004-2006 2539 (36%) 263 (35%) 1205 (37%) 774 (36%) 297 (36%) 
2007-2008 1877 (27%) 176 (24%) 843 (26%) 640 (30%) 218 (26%) 
Synchronous CBCd      
No 6885 (98%) 734 (99%) 3235 (99%) 2115 (98%) 801 (97%) 
Yes 132 (2%) 11 (1%) 48 (1%) 51 (2%) 22 (3%) 






1341 (19%) 88 (12%) 504 (15%) 538 (25%) 211 (26%) 
Danderyd’s University 
Hospitale 
1321 (19%) 266 (36%) 758 (23%) 201 (9%) 96 (12%) 
Stockholm South General 
Hospitale 
961 (19%) 60 (8%) 371 (11%) 385 (18%) 145 (18%) 
Huddinge Hospitale 626 (9%) 66 (9%) 263 (8%) 209 (10%) 88 (11%) 
Capio St. Göran’s 
Hospitale 
1807 (26%) 158 (21%) 918 (28%) 556 (26%) 175 (21%) 
Ersta Hospital and Queen 
Sophia Hospitalf 
664 (9%) 81 (11%) 332 (10%) 185 (9%) 66 (8%) 
Othersg 297 (4%) 26 (3%) 137 (4%) 92 (4%) 42 (5%) 
Tumor size      
0-20 mm 4846 (69%) 539 (72%) 2310 (70%) 1449 (67%) 548 (67%) 
>20-40 mm 1726 (25%) 163 (22%) 804 (24%) 559 (26%) 200 (24%) 
>40  353 (5%) 34 (5%) 134 (4%) 131 (6%) 54 (7%) 
missing 92 (1%) 9 (1%) 35 (1%) 27 (1%) 21 (3%) 
Lymph node metastases      
0 4423 (63%) 478 (64%) 2092 (64%) 1392 (64%) 461 (56%) 
1-3 1738 (25%) 174 (23%) 841 (26%) 503 (23%) 220 (27%) 
>=4 668 (10%) 72 (10%) 261 (8%) 222 (10%) 113 (14%) 
Unknown 188 (3%) 21 (3%) 89 (3%) 49 (2%) 29 (4%) 
Immediate breast 
reconstruction 
     
No 5084 (72%) 540 (72%) 2415 (74%) 1565 (72%) 564 (69%) 
Yes 361 (5%) 17 (2%) 120 (4%) 143 (7%) 81 (10%) 
Unknown 1572 (22%) 188 (25%) 748 (23%) 458 (21%) 178 (22%) 
Radiotherapy       
No 1654 (24%) 138 (19%) 735 (22%) 526 (24%) 255 (31%) 
Yes 5316 (76%) 602 (81%) 2524 (77%) 1626 (75%) 564 (69%) 
Unknown 47 (1%) 5 (1%) 24 (1%) 14 (1%) 4 (0%) 
Chemotherapyh      
No 4362 (62%) 424 (57%) 2033 (62%) 1375 (63%) 530 (64%) 
Yes 2595 (37%) 316 (42%) 1219 (37%) 776 (36%) 284 (35%) 
Unknown 60 (1%) 5 (1%) 31 (1%) 15 (1%) 9 (1%) 
Endocrine therapy      
No 1157 (16%) 130 (17%) 539 (16%) 366 (17%) 123 (15%) 
Yes 5815 (83%) 609 (82%) 2723 (83%) 1787 (83%) 696 (85%) 
Unknown 45 (1%) 6 (1%) 21 (1%) 14 (1%) 4 (0%) 
Follow-up time of vital 
status (years) 
8.9 (2.9) 9.2 (2.9) 9.0 (2.9) 8.7 (2.9) 8.5 (3.1) 
Vital statusi      
Alive 5811 (83%) 640 (86%) 2762 (84%) 1775 (82%) 634 (77%) 
Dead 1206 (17%) 105 (14%) 521 (16%) 391 (18%) 189 (23%) 
Breast cancer-specific 
death 
     
No 6417 (91%) 687 (92%) 3004 (92%) 1990 (92%) 736 (89%) 
Yes 600 (9%) 58 (8%) 279 (9%) 176 (8%) 87 (11%) 
Distant metastasis within 
5 years 
     
No 6521 (93%) 690 (93%) 3064 (93%) 2025 (93%) 742 (90%) 
Yes 496 (7%) 55 (7%) 219 (7%) 141 (7%) 81 (10%) 
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a The median time to surgery for the whole population was 27 days. 
b Charlson Comorbidity Index.  
c Diagnosis of psychiatric disorder before date of breast cancer surgery.  
d Contralateral breast cancer diagnosed within three months of the first breast cancer. 
e University and county hospitals. f Private, non-county hospitals. g All other hospitals where 
study subjects were operated, including all rural hospitals. 
h Chemotherapy=”Yes” also includes women who received trastuzumab since only 148 
women received trastuzumab and all but four of these women received chemotherapy. 
i 119 deaths occurred during 2014 and were thus not classified. The remaining 1087 deaths 
were due to breast cancer (n=600), other cancers (n=125), cardiovascular disease (n=188), 





Table 2. Hazards ratios of overall survival, breast cancer-specific survival, and 
risk of distant metastasis, respectively, in relation to time to surgery  
Overall survival   
n=7017, number of deaths=1206, time at risk=62474 years  
 








HR comparing a 
difference in time to 
surgery of 21 days 
Age-adjusted 1.011 1.007-1.016 <0.001 1.26 
Main modela 1.011 1.006-1.016 <0.001 1.26 
Additionally adjusted for 
questionnaire datab 
1.010 1.006-1.015 <0.001 1.23 
Breast cancer-specific survival   
n=7017, number of breast cancer-specific deaths=600, 
time at risk=57462 years  
 
 









Age-adjusted 1.008 1.001-1.015 0.021 1.18 
Main modela 1.007 1.000-1.014 0.037 1.16 
Additionally adjusted for 
questionnaire datab 
1.007 1.000-1.014 0.048 1.16 
Distant metastasis within 5 years  
n=7017, number of women with distant metastasis=496, 
time at risk=33259 years 
 
 









Age-adjusted 1.009 1.001-1.016 0.021 1.21 
Main modela 1.008 1.001-1.016 0.028 1.18 
Additionally adjusted for 
questionnaire datab 
1.008 1.000-1.015 0.045 1.18 
 
a Adjusted for age, comorbidity according to the Charlson Comorbidity Index, immigration, 
diagnosis of psychiatric disorder, mode of detection, calendar period, synchronous 
contralateral breast cancer, operating hospital, immediate breast reconstruction, tumor size, 
lymph node metastasis, radiotherapy, endocrine therapy and chemotherapy/trastuzumab. 
b Adjusted for all of the factors included in the main model (see above) as well as BMI, 
smoking, education level and LIBRO-1 participation. 
 
A. Linear modela,b 
B. Nonlinear model including restricted cubic splines with 2 degrees of freedoma,b  
C. Nonlinear model including restricted cubic splines with 3 degrees of freedoma,b 
a The median time to surgery, 27 days, is set as reference. 
b All models are adjusted for age, comorbidity according to the Charlson Comorbidity Index, 
immigration, diagnosis of psychiatric disorder, mode of detection, calendar period, 
synchronous contralateral breast cancer, operating hospital, immediate breast 




Table 3. Hazards ratios for risk of death from all causes, breast cancer-specific death, and distant metastasis in relation to 
time to breast cancer surgery, stratified by tumor size and lymph node metastases, respectively 
 
 
Estimate per one 
day’s increase 
 















 Overall survival 
 Deaths=613 
Time at risk=44456 years 
Deaths=451 
Time at risk=14360 years 
Deaths=127 
Time at risk=2797 years 
 
 HR 95% CI  p-value HR 95% CI p-value  HR 95% CI p-value   
Age-adjusted model 1.008 1.001-1.014 0.026 1.012 1.004-1.020 0.002 1.022 1.007-1.037 0.004 0.0084 
Main model
a
 1.007 1.000-1.014 0.052 1.012 1.004-1.020 0.003 1.030 1.014-1.046 <0.001 0.0018 
 Breast cancer-specific survival  
 Breast cancer-specific deaths=228 
Time at risk=40809 years 
Breast cancer-specific deaths=276 
Time at risk=13254 years 
Breast cancer-specific deaths =87 
Time at risk=2602 years 
 
 HR 95% CI  p-value HR 95% CI p-value  HR 95% CI p-value   
Age-adjusted model 1.003 0.992-1.014 0.601 1.008 0.998-1.018 0.131 1.015 0.998-1.033 0.091 <0.0001 
Main model
a
 1.002 0.991-1.013 0.771 1.008 0.998-1.018 0.135 1.025 1.006-1.046 0.012 <0.0001 
 Distant metastasis within 5 years  
 Events=177 
Time at risk=23503 years        
Events=240 
Time at risk=7845 years 
Events=73 
Time at risk=1479 years 
 
 HR 95% CI  p-value HR 95% CI p-value  HR 95% CI p-value   
Age-adjusted model 1.005 0.993-1.018 0.423 1.005 0.994-1.016 0.357 1.018 0.999-1.038 0.067 0.0001 
Main model
a




Adjusted for age, comorbidity according to the Charlson comorbidity index, immigration, diagnosis of psychiatric disorder, mode of detection, 
calendar period, synchronous contralateral breast cancer, operating hospital, immediate breast reconstruction, chemotherapy/trastuzumab, 
radiotherapy, endocrine therapy, and lymph node metastasis. 
 
 
Estimate per one 
day’s increase 
 
No lymph node metastasis 
(n=4423) 
 
1-3 lymph node metastases 
(n=1738) 
 






 Overall survival 
 Deaths=581 
Time at risk=40056 years 
Deaths=305 
Time at risk=15329 years 
Deaths=274 
Time at risk=5085 years 
 
 HR 95% CI  p-value HR 95% CI p-value  HR 95% CI p-value   
Age-adjusted model 1.013 1.006-1.020 <0.001 1.009 0.999-1.018 0.064 1.004 0.995-1.013 0.426 0.0001 
Main model
b
 1.012 1.005-1.019 0.001 1.009 1.000-1.019 0.059 1.003 0.993-1.012 0.562 0.0001 
 Breast cancer-specific survival  
 Breast cancer-specific deaths=206 
Time at risk=36743 years 
Breast cancer-specific deaths=182 
Time at risk=14093 years 
Breast cancer-specific deaths=204 
Time at risk=4744 years 
 
 HR 95% CI  p-value HR 95% CI p-value  HR 95% CI p-value   
Age-adjusted model 1.007 0.995-1.019 0.247 1.003 0.990-1.015 0.682 1.004 0.993-1.015 0.489 0.1624 
Main model
b
 1.005 0.993-1.017 0.412 1.003 0.990-1.015 0.686 1.003 0.993-1.014 0.537 0.1843 
 Distant metastasis within 5 years  
 Events=171 
Time at risk=21395 years 
Events=149 
Time at risk=8184 years 
Events=173 
Time at risk=2784 years 
 
 HR 95% CI  p-value HR 95% CI p-value  HR 95% CI p-value   
Age-adjusted model 1.011 0.998-1.024 0.108 0.999 0.986-1.013 0.933 1.003 0.991-1.014 0.674 0.0781 
Main model
b




Adjusted for age, comorbidity according to the Charlson comorbidity index, immigration, diagnosis of psychiatric disorder, mode of detection, 
calendar period, synchronous contralateral breast cancer, operating hospital, immediate breast reconstruction, chemotherapy/trastuzumab, 
radiotherapy, endocrine therapy, and tumor size.  
